Evidence map›Paper›PMID 37596444›Full record

ArticleJapanese journal of ophthalmology2023

Additive effects of brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients.

Rei Sakata, Shiro Mizoue, Keiji Yoshikawa, Misato Adachi, Shinji Ohkubo, Naoki Hamada, Tomoko Naito, Tomoyuki Muramatsu, Takeshi Hara, Ryo Asato and 1 more

Erratum issuedAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Japanese journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Rei SakataDepartment of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Shiro MizoueDepartment of Ophthalmology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Keiji YoshikawaYoshikawa Eye Clinic, Machida, Tokyo, Japan.
Misato AdachiEye Rose Clinic, Chiyoda, Tokyo, Japan.
Shinji OhkuboOhkubo Eye Clinic, Kanazawa, Ishikawa, Japan.
Naoki HamadaOmiya Hamada Eye Clinic, Saitama, Saitama, Japan.
Tomoko NaitoGrace Eye Clinic, Okayama, Okayama, Japan.
Tomoyuki MuramatsuMuramatsu Eye Clinic, Susono, Shizuoka, Japan.
Takeshi HaraHara Eye Hospital, Utsunomiya, Tochigi, Japan.
Ryo AsatoAsato Eye Clinic, Naha, Okinawa, Japan.
Makoto AiharaDepartment of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. macaihara1126@gmail.com.ORCID http://orcid.org/0000-0001-6810-0583

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination (BBFC) was recently approved for glaucoma and ocular hypertension treatment in Japan. We investigated the efficacy and safety of BBFC used concomitantly with prostaglandin analogs (PG) or a PG/beta-blocker fixed-dose combination (PG/beta FC). STUDY

designThis was a prospective, open-label, multicenter study. PATIENTS AND

methodsWe enrolled Japanese patients with open-angle glaucoma. BBFC (Ailamide) was concomitantly administered to either the PG or the PG/beta FC group, and intraocular pressure (IOP) and safety were evaluated at 4 and 12 weeks. The groups were stratified into low and high IOP baseline groups based on the median baseline IOP.

resultsWe enrolled 100 patients, 91 of whom completed the 12-week follow-up. The mean ages were 67.1 and 65.7 years in the PG group (n = 45, baseline IOP of 15.7 ± 2.3 mmHg) and the PG/beta FC group (n = 46, baseline IOP of 16.3 ± 2.3 mmHg), respectively. After BBFC administration, IOPs at 4 and 12 weeks were 13.0 ± 2.0 and 13.0 ± 2.6 mmHg (P < 0.0001) in the PG group, respectively, and 13.7 ± 2.4 and 13.7 ± 2.2 mmHg (P < 0.0001) in the PG/beta FC group, respectively. IOP decreased by - 2.0 ± 1.8 mmHg (P < 0.0001) and -1.9 ± 1.4 mmHg (P < 0.0001) in the low baseline PG group (14.1 mmHg) and low baseline PG/beta FC group (14.8 mmHg) at 12 weeks, respectively. Sixteen adverse events were identified, all of which were common and did not affect visual acuity.

conclusionsBBFC can be used concomitantly with PG or PG/beta FC to reduce IOP without serious complications.

Indexed as

Glaucoma, Open-AngleOcular HypertensionAntihypertensive AgentsBrimonidine TartrateDrug CombinationsEast Asian PeopleHumansIntraocular PressureProspective StudiesProstaglandins, SyntheticSulfonamidesThiazinesTimololAntihypertensive AgentsBrimonidine TartratebrinzolamideDrug CombinationsProstaglandins, SyntheticSulfonamidesThiazinesTimololBrimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combinationIntraocular pressurePrimary open-angle glaucomaProstaglandin analogsProstaglandin analogs/beta-blocker fixed-dose combination

Identifiers

PMID37596444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.